9-Methyl-5-pyridin-2-ylsulfonyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene;hydrochloride | 1287293-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-Methyl-5-pyridin-2-ylsulfonyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene;hydrochloride
• CAS: 1287293-67-7
• 化学式: C₁₉H₁₉N₃O₂S*ClH
• 分子量: 389.906
• InChiKey: ZFLMLRUPZULJPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  去甲托品酮 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydride 、 potassium carbonate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲醇 、 乙醚 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 生成 9-Methyl-5-pyridin-2-ylsulfonyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene;hydrochloride
  参考文献：
  名称：

  Epiminocyclohepta[b]indole analogs as 5-HT6 antagonists

  摘要：

  A new series of epiminocyclohepta[b]indoles with potent 5-HT6 antagonist activity were discovered and optimized using in vitro protocols. One compound from this series was progressed to advanced pharmacokinetic (PK) studies followed by 5-HT6 receptor occupancy studies. The compound was found to have excellent oral absorption, a highly favorable PK profile and demonstrated pharmacodynamic interaction with the 5-HT6 receptor as shown by ex vivo autoradiography. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.022

文献信息

• [EN] EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ÉPIMINOCYCLOALKYL(B)INDOLE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA SÉROTONINE DE SOUS-TYPE 6 (5-HT6) ET LEURS UTILISATIONS
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2011044134A1

  公开（公告）日：2011-04-14

  The present invention relates to epiminocycloalkyl[b]indole derivatives as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, and methods of preparation and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, and schizophrenia. The subject compounds have the structure of formula (I), with the substituents being described herein.

  本发明涉及作为5-羟色胺亚型6（5-HT6）调节剂的环氨基环巴[b]吲哚衍生物，包括这些化合物的药物组合物，以及其制备和使用方法。这些化合物在治疗包括肥胖、代谢综合征、认知和精神分裂症在内的中枢神经系统疾病中具有用途。所述化合物具有式（I）的结构，其中取代基如本文所述。
• EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF
  申请人：GUZZO Peter R.

  公开号：US20110112122A1

  公开（公告）日：2011-05-12

  The present invention relates to epiminocycloalkyl[b]indole derivatives as serotonin sub-type 6 (5-HT 6 ) modulators, pharmaceutical compositions including these compounds, and methods of preparation and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, and schizophrenia. The subject compounds have the structure of formula (I) with the substituents being described herein.

  本发明涉及作为血清素亚型6（5-HT6）调节剂的环氨基环烷基[b]吲哚衍生物，包括这些化合物的制药组合物，以及其制备和使用的方法。这些化合物在治疗中枢神经系统疾病，包括肥胖症、代谢综合征、认知和精神分裂症方面具有用处。所述化合物具有公式（I）的结构，其中取代基如下所述。
• US8575186B2
  申请人：——

  公开号：US8575186B2

  公开（公告）日：2013-11-05
• Epiminocyclohepta[b]indole analogs as 5-HT6 antagonists
  作者：Alan J. Henderson、Peter R. Guzzo、Animesh Ghosh、Jagjit Kaur、Jia-Man Koo、Kassoum Nacro、Shailaja Panduga、Rashmi Pathak、Bharat Shimpukade、Valentina Tan、Kai Xiang、Jonathan D. Wierschke、Matthew L. Isherwood

  DOI：10.1016/j.bmcl.2012.01.022

  日期：2012.2

  A new series of epiminocyclohepta[b]indoles with potent 5-HT6 antagonist activity were discovered and optimized using in vitro protocols. One compound from this series was progressed to advanced pharmacokinetic (PK) studies followed by 5-HT6 receptor occupancy studies. The compound was found to have excellent oral absorption, a highly favorable PK profile and demonstrated pharmacodynamic interaction with the 5-HT6 receptor as shown by ex vivo autoradiography. (C) 2012 Elsevier Ltd. All rights reserved.